Helping Scientists Control Their Research...Let's Start The Conversation
Shutter fatty liver

Fatty Liver

NAFLD (Non-alcoholic Fatty Liver Disease)

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disorders characterized by excessive lipid accumulation in hepatocytes. Each stage of the disease spectrum has distinctive histopathological characteristics. The beginning stages include simple hepatic steatosis, which is characterized by fat droplet accumulation in hepatocytes and this is usually benign and asymptomatic. The disease may progress further to non-alcoholic steatohepatitis (NASH), which may include hepatocellular injury, ballooning (i.e. cellular swelling) and/or inflammation. If left unchecked, NASH can lead to fibrosis, cirrhosis, and ultimately HCC, thus affecting overall liver function.

In spite of the enormous amount of research in the field of NAFLD/NASH in the past decade, the precise mechanisms underlying the development of NAFLD and its progression to NASH have not been completely elucidated, including its link to metabolic syndrome, requiring additional studies and models to elucidate its pathophysiology. Because of its growing worldwide prevalence, various animal models that mirror both the pathophysiology and the histopathology of each stage of NAFLD/NASH are available. Certain dietary approaches can drive NAFLD/NASH in rodent models to mimic human disease and produce different severities of disease along the NAFLD spectrum, and depending on the dietary manipulations, likely work by unique mechanisms. This is essential in determining how the disease progresses, and also helps in evaluating different therapeutic approaches towards the treatment of specific stages of NAFLD. To read more, see our  Product Literature

Our Latest Publication

Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models
Sridhar Radhakrishnan, Jia-Yu Ke, Michael A Pellizzon
Current Developments in Nutrition, Volume 4, Issue 6, June 2020

Joint RDI/Taconic NAFLD Webinar

In case you missed it, here is the link to the presentation, "Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease (NAFLD) in Rodents." Presented by Dr. Sri Radhakrishnan.

ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is a complex spectrum of disorders ranging from simple benign steatosis to more aggressive forms of nonalcoholic steatohepatitis (NASH) and fibrosis. Although not every patient with NAFLD/NASH develops liver complications, if left untreated it may eventually lead to cirrhosis and hepatocellular carcinoma. Purified diets formulated with specific nutritional components can drive the entire spectrum of NAFLD in rodent models. Although they may not perfectly replicate the clinical and histological features of human NAFLD, they provide a model to gain further understanding of disease progression in humans. Owing to the growing demand of diets for NAFLD research, and for our further understanding of how manipulation of dietary components can alter disease development, we outlined several commonly used dietary approaches for rodent models, including mice, rats, and hamsters, time frames required for disease development and whether other metabolic diseases commonly associated with NAFLD in humans occur.

4 Effects Of Dietary Fructose, Total And Saturated Fat, And Cholesterol 4 2 1 Effects Of High Fat Diets, High Fructose Diets, And Combined High Fat, Fructose And Cholesterol Diets On Markers Of Nafld 4
4 Effects Of Dietary Fructose, Total And Saturated Fat, And Cholesterol 4 2 1 Effects Of High Fat Diets, High Fructose Diets, And Combined High Fat, Fructose And Cholesterol Diets On Markers Of Nafld 4
6 Summary Of Commonly Used Diets And Their Expected Effects On Nafld Nash In Rats And Mice 4 6 Summary Of Commonly Used Diets And Their Expected Effects On Nafld Nash In Rats And Mice 4

Ready to speak with a scientist?

Laurag

Laura Griffin, Ph.D.

Project Manager and Scientist
Dima 1010

Dima Paone, MB BCh.

Global Logistics Director and Scientist
Mike 0923

Michael A. Pellizzon, Ph.D.

Senior Scientist
手机牛牛游戏